STOCK TITAN

Charles River Laboratories International, Inc. - CRL STOCK NEWS

Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.

Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.

Charles River operates through three main segments:

  • Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
  • Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
  • Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.

The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.

Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.

Rhea-AI Summary

Charles River Laboratories has launched new Modular and Fast Track viral vector technology transfer frameworks. These frameworks are designed for seamless tech transfer to its Maryland-based viral vector Center of Excellence within nine months. The Fast Track framework allows for straightforward transfers when no process changes are needed, while the Modular framework supports complex transfers requiring process modifications. Both frameworks aim to prevent costly delays and ensure program success. Charles River's CoE offers full-scale capabilities for adeno-associated virus, adenovirus, lentivirus, and retrovirus production and integrates their concept-to-cure portfolio from discovery to commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
Rhea-AI Summary

Charles River Laboratories reported first-quarter 2024 results with revenue of $1.01 billion, GAAP EPS of $1.30, and Non-GAAP EPS of $2.27. The company updated its 2024 guidance and reaffirmed revenue growth and non-GAAP earnings per share estimates. Despite revenue declines in the DSA segment, the RMS and Manufacturing segments showed growth. The company aims to capitalize on new business opportunities in the biopharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
-
Rhea-AI Summary

Charles River Laboratories International, Inc. (NYSE: CRL) has launched viral vector reference materials to aid gene and cell therapy researchers, providing AAV and LVV products with high quality. The company aims to streamline the research and development process, offering superior serotypes and vector genome concentrations. The launch includes six AAV reference material serotypes and five LVV reference material products, contributing to their extensive CDMO offerings. The official launch will take place at the ASGCT Annual Meeting in May 2024, showcasing case study data and various presentations. Charles River's CGT portfolio and viral vector CDMO solutions aim to support client programs and assist in scaling from pre-clinical to commercial stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
Rhea-AI Summary
Charles River Laboratories (NYSE: CRL) has achieved 100% renewable electricity usage globally ahead of schedule, marking significant progress towards climate goals. The company joined RE100 in 2020 and committed to operating on 100% renewable electricity globally by 2030. Through virtual power purchase agreements in the US and Europe, Charles River now leads in sustainable energy practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories launches Alternative Methods Advancement Project to reduce reliance on animal testing with a $500 million investment, focusing on innovation, partnerships, and advocacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) is set to release its first-quarter 2024 financial results on May 9th, with a conference call scheduled for 8:30 a.m. ET. Investors can access the live webcast and replay on the Company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) launches Patholytix Foresight, an AI decision support tool in collaboration with Deciphex. The tool enhances toxicologic pathology assessment, accelerates primary evaluation, and peer review in drug discovery. Patholytix Foresight streamlines workflows, improves efficiency, consistency, and accuracy in analyzing histopathology data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
AI
-
Rhea-AI Summary
Charles River Laboratories International, Inc. collaborates with Axovia Therapeutics to produce High Quality gene of interest plasmid to support gene therapy trials for Bardet-Biedl Syndrome. Axovia's lead program, AXV101, shows promising results in preclinical studies for BBS. The collaboration aims to develop transformative therapies for ciliopathies, a group of complex disorders affecting 1 in 1,000 people.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) partners with Ship of Theseus to manufacture GMP plasmid DNA for therapeutic use targeting various indications. Ship of Theseus focuses on HOX family biologics for tissue repair and maintenance. The collaboration aims to develop treatments for diabetic and chronic wounds, neutropenia, psoriasis, androgenetic alopecia, women’s health, infertility, and epithelial cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) is showcasing new tools and services at the AACR Annual Meeting to support oncology research. The company is highlighting technology-driven capabilities, including the Apollo™ Price Estimator and the Cancer Model Database. Charles River will also present scientific posters and host a spotlight session on predictive tumor models and therapeutic antibody platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none

FAQ

What is the current stock price of Charles River Laboratories International (CRL)?

The current stock price of Charles River Laboratories International (CRL) is $187.9 as of November 20, 2024.

What is the market cap of Charles River Laboratories International (CRL)?

The market cap of Charles River Laboratories International (CRL) is approximately 10.6B.

What services does Charles River Laboratories provide?

Charles River provides research models, discovery and safety assessment services, and manufacturing support, including microbial solutions, biologics testing, and avian vaccine services.

When was Charles River Laboratories founded?

Charles River Laboratories was founded in 1947.

Who are Charles River Laboratories' primary clients?

The company's primary clients are pharmaceutical and biotechnology companies, government agencies, and leading academic institutions.

What is Charles River Laboratories' mission?

Charles River's mission is to accelerate research and drug development efforts globally.

What is included in the Research Models & Services segment?

This segment includes providing laboratory animal models with specific genetic traits for preclinical studies.

What does the Discovery & Safety Assessment segment offer?

This segment offers services for the early development of new drugs, including discovery services and safety assessments.

What are some of the services provided under Manufacturing Support?

Manufacturing Support includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services.

How does Charles River contribute to the healthcare industry?

Charles River helps expedite the discovery and development of new therapies, aiding in research and the safe manufacture of new drugs.

What makes Charles River Laboratories a trusted partner in the life sciences industry?

The company's commitment to excellence, innovative approach, and comprehensive service offerings make it a trusted partner.

What is the ticker symbol for Charles River Laboratories International, Inc.?

The ticker symbol for Charles River Laboratories International, Inc. is CRL.

Charles River Laboratories International, Inc.

NYSE:CRL

CRL Rankings

CRL Stock Data

10.63B
50.64M
0.92%
103.97%
3.62%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
WILMINGTON